Neogen Corporation (NEOG) financial statements and ratios from SEC XBRL: revenue $0.9B (TTM), net margin -0.9%, revenue growth -2.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $870.40M |
| Revenue (TTM) | $0.9B |
| Net Margin | -0.9% |
| Operating Margin (TTM) | -2.5% |
| Net Debt / EBITDA | 6.7 |
| Revenue Growth (YoY) | -2.7% |
| EPS Growth (YoY) | -99.2% |
| FCF Growth (YoY) | -168.8% |
| EV / EBITDA | 33.2 |
| Price / Book | 1.21 |
| Price / Sales | 2.92 |
| FCF Yield | 1.3% |
| Altman Z-Score | 1.39 (distress) |
| Piotroski F-Score | 6/9 |
| Piotroski checks passed | 6 of 9 |
| Industry P/E (Pharmaceutical Products) | 17.1 |
| Sector P/E (Healthcare) | 21.6 |
NEOG overview · NEOG earnings · NEOG KPIs · NEOG documents · NEOG ownership · NEOG peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.